Muna Bhanji sold $2,253 of NTLA
director at Intellia Therapeutics, Inc.. 265 shares at an average of $8.50, traded Apr 29, 2025, filed May 1, 2025.
Score components
- +15RoleDirector
- 0Trade size$2k at market
- 0Share of holdings soldSold 1.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-061881, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 29, 2025 | SOpen-market sale Common Stock10b5-1 | -265 | $8.50 | $2,253 | 19,203 | May 1, 2025 |
Related signals
Other insiders at Intellia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NTLAsell Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $23k 1,864 shares | -3% | |
| 58Moderate | NTLAbuy Intellia Therapeutics, Inc. | William J Chase director | $1.0M 100,000 shares | +288% | |
| 32Weak | NTLAsell Intellia Therapeutics, Inc. | Edward J Dulac III EVP, Chief Financial Officer | $105k 7,462 shares | -7% | |
| 30Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $10k 1,022 shares | -1% | |
| 30Weak | Intellia Therapeutics, Inc. | Michael P Dube VP, Chief Accounting Officer | $25k 2,503 shares | -4% | |
| 20Weak | Intellia Therapeutics, Inc. | Jesse Goodman director | $29k 3,094 shares | -11% | |
| 23Weak | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $23k 2,572 shares | -2% | |
| 23Weak | Intellia Therapeutics, Inc. | Eliana Clark EVP, Chief Technical Officer | $6,104 679 shares | -1% | |
| 0Weak | Intellia Therapeutics, Inc. | Muna Bhanji director | $2,642 265 shares | -1% | |
| 39Weak | Intellia Therapeutics, Inc. | James Basta EVP, General Counsel | $86k 7,074 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.